| Business/Economy |
Govt putting price on mother's love? -
Jaya Shroff Bhalla, Pioneer
The Government is considering a bizarre proposal to give doles to housewives for their toil at home. But the proposal, which would reduce housewives to the status of salaried workers, has drawn sharp criticism from women activists. Making a fresh bid for the Bill proposing “honorarium” for housewives, Minister for Women and Child Development Krishna Tirath has shot off letters to the Ministry of Statistics and Programme Implementation (MOSPI) and Labour Ministry to “recognise and make visible the full extent of work of women.” |
Colonisation, the phoney-money way -
S Gurumurthy, Business Line
As the rupee threatens to fall to Rs 60 per US dollar, the Finance Minister is running around the world seeking foreign investment into India to get enough dollars to defend the rupee. Meanwhile, the public simply doubled the quantum of imports in April 2013 mocking the Government’s desperate attempts to stanch the flow through repeated hikes in import duty over the last one year. . To bring down gold imports, the Finance Minister is advising Indians to buy stocks and not gold, but they are not obliging. |
It's all in the mindsets -
R Gopalakrishnan, Business Standard
InnoColumn will explore practices of real innovators in a practical rather than in an academic mode. I hope it will come through easy-to-read and thought-provoking. In my first article, let's examine the concept of "growth mindset". Why should innovators have a "growth mindset"? |
The unhealthy legacy of process patents -
Bhupesh Bhandari, Business Standard
Mumbai's Jaslok Hospital has advised its doctors not to prescribe medicine made by Ranbaxy Laboratories to their patients. Apollo Pharmacy, the country's largest chain of drug stores, has stopped selling Ranbaxy medicine and has suspended procurement from the company. This comes after Ranbaxy, now majority-owned by Daiichi Sankyo of Japan, paid $500 million in the US for fudging data while seeking approvals from the Food and Drug Administration to launch products there. |
Maxis case: CBI to charge Maran? -
Times of India
The Central Bureau of Investigation is on the verge of wrapping up its its investigations into the Aircel-Maxis deal and will be naming DMK leader DayanidhiMaran and Maxis owner T AnandaKrishnan as an accused in its chargesheet. |
Going down the wrong road -
Pradeep S Mehta, Business Line
According to some, the idea of a road regulator does not make sense. On the other hand, we do need an exclusive body to deal with problems in all types of Public Private Partnership (PPP) contracts, which include roads. The Finance Minister in his Budget speech early this year, inter alia, proposed a regulator for the road sector, mainly for three reasons: financial stress faced by the developers; contract management and renegotiation to sort out the problems of existing contracts; and enhanced construction risk. |
Industrial production dogged by data issues -
Kunal Kumar Kundu, Bus Std
India released its industrial production (IP) data for April on Wednesday. With an annual growth rate of 1.95 per cent, IP grew for a fourth consecutive month, after having contracted during six out of the previous nine months. |
Investors continue to buy India's consumption story -
Viveat Susan Pinto & Reghu Balakrishnan, Business Standard
Private equity (PE) investors haven't lost their appetite for consumer goods companies despite the consumption story taking a few knocks in the past few quarters. A recent study by Fitch group company India Ratings & Research shows the growth rate of domestic private consumption has been at its lowest at 3.68 per cent in 34 quarters. This, the study says, is becoming a well-entrenched trend. |
Sun to pay $550m to Pfizer, Takeda -
Times of India
India's largest drug maker by market capitalization Sun Pharma on Wednesday said that it will pay Pfizer and Japanese drug maker Takeda $550 million jointly to settle a patent infringement suit in the US on generic pantoprazole, an anti-acidity medicine. This is part of $2.15 billion damages which Israeli drug maker Teva and Sun Pharma will pay jointly to settle a lawsuit related to acid-reflux drug Protonix to Pfizer and Takeda Pharmaceutical. Takeda, Pfizer's partner on the drug, will receive 36%, or about $774 million from the settlement. |
New cyber security body to rope in ISPs -
Indrani Bagchi, Times of India
Indian government is rolling out a new cybersecurity architecture at a time when it turns out that India is among the top five countries whose data has been compromised by the US' NSA surveillance system. The new architecture, which was cleared by the Cabinet last month, envisages an interconnected set of organizations in key departments like NTRO, defence and home ministries, while CERT will remain the umbrella body to oversee cyber-protection.
|
|
|
|
|
|
|
LensOnNews, Opinion
 |
LensOnElections |
|
|
|
|
| |
|
|
|
